3K3A-APC

N/A

Report date: 2024/10/12 09:12:41

Base Information

Drug Name3K3A-APC
Drug Alias Name3K3A-activated protein C3K3A-APC non-anticoagulant mutant - ZZ BiotechActivated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-BiotechHuman-recombinant-3K3A-APCRecombinant variant of human activated protein C (3K3A-APC)-ZZ-Biotech +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionProtein C replacementsCoagulation factor VIII inhibitorsFactor Va inhibitors
TargetsCoagulation factor VCoagulation factor VIII
Therapy Area/IndicationsIschemic StrokeAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaAustria
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSocratechUniversity Of Southern CaliforniaThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesDermatherix Pty LtdMacquarie UniversityZz Biotech Llc
Inactive CompaniesUniversity Of Southern California
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsIschemic Stroke

Other Information

ATC CodeN/A
Related LinksN/A